(p. A13) The Food and Drug Administration has declared a nationwide shortage of Adderall, a medication used to treat A.D.H.D. that has had surging demand in recent years.
. . .
Adderall, which contains the stimulant amphetamine, is a controlled substance and highly regulated, so it is difficult for pharmacies to quickly pivot and carry new brands, analysts said.
. . .
While a number of companies make Adderall and generic versions, pharmacies may find it difficult to pivot to other suppliers because of amphetamine’s status as a controlled substance that typically includes restrictions on its use and monitoring of prescription orders. Any given pharmacy might risk raising red flags with the Drug Enforcement Administration by doubling its supply, said Erin Fox, an expert on drug shortages at the University of Utah.
“With a controlled substance, it’s harder for patients to call around and find a pharmacy that has product for them,” Ms. Fox said.
For the full story, see:
(Note: ellipses added.)
(Note: the online version of the story has the date Oct. 13, 2022, and has the title “F.D.A. Confirms Wide Shortage of Adderall.”)